Drug intelligence / Profile preview

CIN-105

Development stage: Preclinical
Lead developer: CinRx Pharma
Modality: Small Molecules

Overview

CIN-105 is an investigational cardiovascular drug candidate from CinRx Pharma that is currently in preclinical development for cardiovascular diseases. While detailed structural, mechanistic, and formulation information have not been publicly disclosed, CIN-105 is positioned within CinRx’s small-molecule pipeline and is being advanced as a pharmaceutical therapy for cardiovascular indications, with development status reported as preclinical in public pipeline databases.

Beyond the preview

Go deeper on CIN-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIN-105.

Explore the full profile